FDA
-
-
-
-
-
-
-
Valion Bio (Nasdaq:VBIO): Oral Mucosal Entolimod Could Offer a New Needle-Free Deployment Path to Support Growing Need for Scalable Civilian Radiation Preparedness Should Nuclear Infrastructure Expand
-
-
-
-
-
-
-
Valion Bio names CFO Lisa Wolf as president and COO after CEO exits
-
-
-
-
-
-
-
Ukraine Ministry of Health Accepts Entolimod Dossier for Formal Review Under Regulatory Equivalence Pathway
-
-
-
-
-
-
-
Valion Bio notes House committee directive on radiation countermeasures
-
-
-
-
-
-
-
Valion Bio Celebrates Grand Opening of Velocity Bioworks Biomanufacturing Facility in San Antonio, Anchoring Domestic Production of Entolimodâ„¢
-
-
-
-
-
-
-
Vitality Biopharma Inc. (VBIO) Files for up to $5M Offering
-
-
-
-
-
-
-
Vitality Biopharma Announces Neural Repair Treatment Patent Filings
-
334,854 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


